Hana A Al-Abdulkarim
Biographic Data
| ID | 10003286 |
|---|---|
| NAME | Hana A Al-Abdulkarim |
| GIVEN NAMES | Hana A |
| FAMILY NAME | Al-Abdulkarim |
| SIGNATURE | AL-ABDULKARIM H A |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Healthcare systems and health economics in GCC countries
Following the discovery of oil, citizens of the Cooperation Council for the Arab States of the Gulf (GCC), which includes Bahrain, Kuwait, Qatar, Oman, the United Arab Emirates, and Saudi Arabia, have enjoyed the benefits of universal healthcare. However, as the population and healthcare demands in the GCC continue to grow, financing these healthcare systems without adequately considering the value of reimbursed health technologies and the effect…
Rare disease challenges and potential actions in the Middle East
Rare diseases present challenges in the MENA region and globally, requiring focused attention and innovative solutions. By implementing comprehensive strategies that consider both economic efficiency and fairness, healthcare systems can better serve rare disease patients and improve their quality of life
Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
Background The advent of Basaglar ® , which is a biosimilar insulin glargine formulation for Lantus ® has brought hope that it will result in similar outcomes and lower costs. However, some health practitioners raised some concerns about the therapeutic equivalence of this new biosimilar. Therefore, we aimed to examine the clinical and financial impact of switching from Lantus ® to Basaglar ® . Methods This was a single–center retrospective chart…
No prominent works on this page.
Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia
Background The advent of Basaglar ® , which is a biosimilar insulin glargine formulation for Lantus ® has brought hope that it will result in similar outcomes and lower costs. However, some health practitioners raised some concerns about the therapeutic equivalence of this new biosimilar. Therefore, we aimed to examine the clinical and financial impact of switching from Lantus ® to Basaglar ® . Methods This was a single–center retrospective chart…
Healthcare systems and health economics in GCC countries
Following the discovery of oil, citizens of the Cooperation Council for the Arab States of the Gulf (GCC), which includes Bahrain, Kuwait, Qatar, Oman, the United Arab Emirates, and Saudi Arabia, have enjoyed the benefits of universal healthcare. However, as the population and healthcare demands in the GCC continue to grow, financing these healthcare systems without adequately considering the value of reimbursed health technologies and the effect…
Rare disease challenges and potential actions in the Middle East
Rare diseases present challenges in the MENA region and globally, requiring focused attention and innovative solutions. By implementing comprehensive strategies that consider both economic efficiency and fairness, healthcare systems can better serve rare disease patients and improve their quality of life
Economic growth (2 works) · Economics (2 works) · Health care (2 works) · Medicine (2 works) · Public health (2 works) · Computer Science (1 work) · Diabetes Management and Research (1 work) · Diabetes mellitus (1 work) · Diabetes Treatment and Management (1 work) · Disease (1 work)